HPLC-UV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-10. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
==== Insecticides ==== Scientists are actively seeking methods for controlling the cabbage looper. Known as an evolutionary arms race, scientists are constantly researching ways to control the cabbage looper while the looper evolves resistance to the management methods. Synthetic insecticides are relatively effective; however, many of them are banned for their toxicity. One exception is Ambush. Studies have shown that this pyrethroid insecticide is effective at killing cabbage looper eggs, and its usage is permitted in the US. Other studies have explored the usage of biological insecticides; for example, a polyhedrosis virus was shown to be effective. Unfortunately, managing large quantities of this virus would be difficult, so it is not a feasible option. An effective option is to use synthetic and biological insecticides together; this method seems to both control the population and slow the development of resistance, but it still requires the usage of toxic chemicals. Currently, spraying Bacillus thuringiensis is considered to be the best option, possibly with NPV for an added benefit, but cabbage looper is growing increasingly more resistant to B. thuringiensis. Recent studies, however, have demonstrated that cabbage loopers resistant to B. thuringiensis are twice as susceptible to NPVs, which provides insight into novel biological control methods.
== History == In the first half of the 20th century, Turner and Winks discovered that borosilicate glasses can be leached by acids. Their investigations showed that not only the chemical stability can be influenced by thermal treatment but also density, refractive index, thermal expansion and viscosity. In 1934, Nordberg and Hood discovered that alkali borosilicate glasses separate in soluble (sodium borate rich) and insoluble (silica rich) phases if the glass is thermally treated. By extraction using mineral acids the soluble phase can be removed and a porous silica network remains. During a sintering process after extraction, a silica glass is generated, which has properties approaching those of quartz glass. The manufacturing of such high-silica glasses has been published as the VYCOR-process.
Narrated by Alun Lewis, directed by Gary Leach, produced by Geoff Deehan, produced by Sandlin Productions 24 November The Dyslexic Engineer, about Ben Bowlby, born on 2 November 1966; his VS91 car at Snetterton Circuit, with a Vauxhall Astra engine, with footage mostly from the end of the earlier documentary in September 1990; his studies at the Polytechnic of East London; Richard Bowlby, his father from Hampstead, who also realised that he was dyslexic; Rosalind Rathouse, his former remedial teacher; Roy Greenfield, a retired maths teacher from King Alfred School, London, who believed that perhaps people would adapt to mathematics more if the subject was taught later in life, as people are often put off the subject at secondary school; Ben gained nine O-levels but couldn't acquire Mathematics A-level above grade E after, two attempts; Xenia Bowlby; his polytechnic course tutor, Alan Slawson, and limited-slip differentials; his car raced in the Clubman (racing car class); he was sponsored by Ripspeed clothing and Spax Performance shock absorbers; Eric Broadly of Lola Cars; he joined Lola Cars in October 1991; he had attempted to gain a place at Lancaster University to study Engineering; Mike Blanchet of Lola Cars; empirical research in designing and building motor racing cars; Mark Williams, head of Formula 3000 at Lola Cars. Narrated by Ian Holm, produced by Michael Proudfoot, directed by Patrick Uden, made by Uden Associates.
== Workflow == The Lanthanide group of elements are used for tagging antibodies, as the background in biological samples is very low. When choosing the appropriate isotope for the biomarker, low expression biomarkers should be paired with an isotope that has high signal intensity. If a less pure isotope must be used, it should be paired with a low expression biomarker, to minimize any non specific binding or background. Isotope polymers are constructed using diethylenetriaminepentaacetic acid (DTPA) chelator to bind ions together. The polymer terminates with a thiol or a maleimide that links it to reduced disulfides in the Fc region of the antibody. Four to five polymers are bound to an antibody, resulting in about 100 isotope atoms per antibody. Tagged antibodies may be in solution, conjugated to beads, or surface immobilized. The cell staining follows the same procedures as in fluorescent staining for flow cytometry. To distinguish between live and dead cells, cells can be probed with rhodium, an intercalator which can only penetrate dead cells. Then all cells are fixed and stained with iridium, which penetrates all cells, to be able to visualize which are alive. The cell introduction method of the mass cytometer is an aerosol splitter injection. The cells are then captured in a stream of argon gas, then transported to the plasma where they are vaporized, atomized, and ionized. The cell is now a cloud of ions, which passes into the ion optics center. Then a time of flight analyzer is used to measure the mass of the ions.
Sources: en.wikipedia.org
grhl2b loss causes apoptosis throughout the brain and the nervous system of zebrafish. A similar result came from a mouse study and led to the belief that grhl2b is a key survival factor for neural cells.
=== Extraction and phase transfer using droplet microfluidics === Liquid-liquid extraction is a method used to separate an analyte from a complex mixture; with this method compounds separate based on their relative solubility in different immiscible liquid phases. To overcome some of the disadvantages associated with common bench top methods such as the shake-flask method, Microfluidic liquid-liquid extraction methods have been employed. Microfluidic droplet-based systems have demonstrated the capability to manipulate discrete volumes of fluids in immiscible phases with low Reynolds numbers. and laminar flow regimes. Microscale methods reduce time required, reduce sample and reagent volume, and allow for automation and integration. In some studies, the performance of droplet-based microfluidic extraction compares closely with the shake-flask method. A study which compared the shake-flask and microfluidic liquid-Liquid extrication methods for 26 compounds and found a close correlation between the values obtained (R2= 0.994). It has also been demonstrated that microfluidic liquid-liquid extraction devices can be integrated with other instruments for detection of the extracted analytes. For example, microfluidic extraction could be used to extract an analyte initially in an aqueous phase such as cocaine in saliva then interfaced with on-chip IR spectroscopy for detection.
== The syndrome == MMF was originally described as a syndrome, with myalgia, arthralgia, marked asthenia, muscle weakness and fever as symptoms. Patients tend to have elevated creatine kinase, erythrocyte sedimentation rate, and a myopathic electromyograph.
Sources: en.wikipedia.org
==== Adverse effects ==== An FDA warning in March 2014 about possible cognitive adverse effects of PCSK9 inhibition caused concern, as the FDA asked companies to include neurocognitive testing into their Phase III clinical trials.
== Signs and symptoms == A Jarisch–Herxheimer reaction usually manifests in 1–3 hours after the first dose of antibiotics as fever, chills, rigor, hypotension, headache, tachycardia, hyperventilation, vasodilation with flushing, myalgia (muscle pain), exacerbation of skin lesions and anxiety. The intensity of the reaction indicates the severity of inflammation. Reaction commonly occurs within two hours of drug administration, but is usually self-limiting. Jarisch–Herxheimer reactions may present with similar symptoms to conditions such as allergic reaction and sepsis. Compared to sepsis, recovery from Jarisch–Herxheimer reaction tends to be much more rapid and rarely requires interventions such as vasopressors to increase blood pressure.
The Jammu region, while less affected, also experienced a reduction in visitors during periods of heightened unrest. Episodes of violence and terror attacks have repeatedly disrupted the sector, leading to mass cancellations and long-term damage to the region's image as a safe destination. Notably, the 2019 advisory from the Government of India, following the abrogation of Article 370, resulted in the abrupt evacuation of tourists and a near-complete shutdown of the industry. Terror attacks such as the 2025 Pahalgam attack, which resulted in significant loss of life, have led to widespread cancellations, a sharp decline in bookings, and the closure of many tourist sites as part of security measures. The immediate aftermath of such incidents typically sees a steep drop in tourist arrivals, with ripple effects on employment and local businesses dependent on tourism. The sector’s recovery often takes several years, and recurring instability continues to act as a major constraint on its full potential. Despite these challenges, the region has demonstrated resilience, with tourism numbers rebounding during periods of relative calm. Periods of decrease in violence boosts tourism. In 2024, Jammu and Kashmir recorded over 23 million tourist visits. However, the volatility associated with insurgency is a persistent obstacle to sustainable tourism development.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.